Nicki Kyriacou is a PhD candidate within the Sydney Pharmacy School at The University of Sydney, Australia. In 2020, she obtained her Bachelor of Advanced Science (Honours) degree (Chemistry, Physiology) at the University of New South Wales, Australia. Following this, Nicki worked for GSK where she supported the Ethnopharmacology Team in the Clinical Pharmacology Modelling & Simulation group in profiling ethnic sensitivity for GSK R&D. Nicki’s PhD project investigates the interrelationship between ethnicity/geographic ancestry and the pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors used in oncology.

Dr Machel Leuschner is a pharmacologist and lecturer in the Department of Pharmacology at the University of Pretoria, South Africa. She holds a BPharm degree, a Master’s degree in Pharmaceutical Chemistry, and a PhD in Pharmacology. Her research focuses on LC-MS/MS–based bioanalytical method development to support clinical pharmacology, including drug phenotyping, microsampling strategies, and precision medicine applications. She has a particular interest in pharmacovigilance, pharmacogenomics and translational approaches relevant to diverse populations. Dr Leuschner is actively involved in postgraduate training, clinical research capacity development, and pharmacogenomics stakeholder engagement to advocate for responsible evidence based PgX implementation in Southern Africa.

Lauren is an early career scientist and University of Western Australia graduate, who currently works within the Clinical Biochemistry, Pharmacology and Toxicology department at PathWest Laboratory Medicine in Perth, Western Australia. She has spent her early career involved in method development and research within Pharmacology and Toxicology disciplines. Her project in collaboration with PathWest Clinical Biochemistry, University of Western Australia and Curtin University Medical Schools, explores the benefits of a new approach to fluoropyrimidine dosing in Australia. Combining plasma uracil phenotype screening and 5-fluorouracil therapeutic drug monitoring, to supplement genotyping and better support personalised cancer therapy and improve patient outcomes.

Noha Kamel is a PhD student at School of Pharmacy, the University of Sydney. Her thesis focuses on quality use of medicine in patients with CKD. She is presenting a review in collaboration with GSK that is part of her PhD project.

Alice is a third-year PhD candidate at Monash University focusing on the optimisation of dosing regimens of antibiotics to overcome the antimicrobial resistance crisis. She has been the Student Representative of both the Population Approach Group of Australia and New Zealand (PAGANZ) and the ASCEPT Drug Disposition and Response Special Interest Group.

Dr. Shomita Shetty, Pharm.D., specializes in Oncology Therapeutics and Clinical Pharmacology. Her research integrates translational and observational oncology with pharmacokinetic analysis to enhance dosing strategies and improve patient outcomes in cancer care.